Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.69 |
| ▸ | PNMT | P11086 | 1/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | DRD1 | P21728 | 2/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | DRD5 | P21918 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6341558 | 0.88 | TAAR1 (0.53) | TAAR1PNMTSIGMAR1MAPTMAPK1 | |
| SCHEMBL295912 | 0.84 | PNMT (0.48) | TAAR1PNMTSIGMAR1MAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL5958057 | 0.83 | CSNK2A1 (0.47) | TAAR1PNMTSIGMAR1MAPTMAPK1 | |
| SCHEMBL793707 | 0.83 | TAAR1 (0.69) | TAAR1PNMTSIGMAR1KDM4EADRA2A | |
| SCHEMBL29042669 | 0.83 | PNMT (0.47) | TAAR1PNMTSIGMAR1MAPTMAPK1 | |
| SCHEMBL184185 | 0.82 | TAAR1 (1.00) | TAAR1PNMTSIGMAR1KDM4EADRA2A | |
| SCHEMBL17552718 | 0.81 | PNMT (0.45) | TAAR1PNMTSIGMAR1MAPTMAPK1 | |
| SCHEMBL530150 | 0.81 | PNMT (0.45) | TAAR1PNMTSIGMAR1MAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL3271461 | 0.81 | TAAR1 (0.67) | TAAR1PNMTSIGMAR1KDM4EADRA2A | |
| SCHEMBL3978582 | 0.81 | MAPT (0.47) | TAAR1PNMTSIGMAR1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111848494-B | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-3131877-B1 | BIGUANIDE COMPOUNDS | IMMUNOMET THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| CN-111848494-A | Guanidine compounds and uses thereof | 伊谬诺米特医疗有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| EP-3131877-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | Immunomet Therapeutics Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| WO-2016095088-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2015160220-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-10-22 | — | — | WO | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| WO-2004096134-A2 | SUBSTITUTED 1,4-DIAZEPINES AND USES THEREOF | ORTHO-MCNEIL PHARMACEUTICALS, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| CN-1307584-A | Macrolide LHRH antagonists | ABBOTT LAB (US) | 2001-08-08 | — | — | CN | disclosed |
| EP-1066307-A1 | 3',3'-N-BIS-SUBSTITUTED MACROLIDE LHRH ANTAGONISTS | ABBOTT LABORATORIES (US) | 2001-01-10 | — | — | EP | disclosed |
| EP-1066304-A1 | MACROLIDE LHRH ANTAGONISTS | ABBOTT LABORATORIES (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-2000012522-A1 | MACROLIDE LHRH ANTAGONISTS | ABBOTT LABORATORIES (US) | 2000-03-09 | — | — | WO | disclosed |
| US-6020521-A | Macrolide LHRH antagonists | ABBOTT LABORATORIES (US) | 2000-02-01 | — | — | US | disclosed |
| US-5972898-A | ERYTHROMYCIN A DERIVATIVES AS LUTENIZING HORMONE RELEASING HORMONE (LHRH) ANTAGONISTS, AND METHODS OF THEIR PREPARATION | ABBOTT LABORATORIES (US) | 1999-10-26 | — | — | US | disclosed |
| WO-1999050275-A2 | MACROLIDE LHRH ANTAGONISTS | ABBOTT LABORATORIES (US) | 1999-10-07 | — | — | WO | disclosed |
| WO-1999050276-A1 | 3',3'-N-BIS-SUBSTITUTED MACROLIDE LHRH ANTAGONISTS | ABBOTT LABORATORIES (US) | 1999-10-07 | — | — | WO | disclosed |
| US-5955440-A | 3'-N-DESMETHYL-3'-N-SUBSTITUTED-6-O-METHYL-11-DEOXY-11,12-CYCL IC CARBAMATE ERYTHROMYCIN A DERIVATIVES | ABBOTT LABORATORIES (US) | 1999-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | PC, TFAM, PCK2 | TAAR1 4576/4885PNMT 545/4885SIGMAR1 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.